Abstract: Provided are a compound III serving as an LSD1 inhibitor and a crystal form thereof, as well as use of the compound and the crystal form thereof in preparation of a medicament for treating an LSD1 related disease.

Abstract: Disclosed are 6-carbamate substituted heteroaryl ring derivatives and a preparation method therefor. The present application particularly relates to a compound as shown in formula (II) and a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a thiophene compound and an application thereof. The present invention specifically relates to a compound represented by formula (II) and a pharmaceutically acceptable salt thereof, wherein L1 is —C(?O)— or —C(?O)—NH—; R1 is R1a or aa; ring A is bb or cc; R1a is C1-3 alkyl substituted with 1, 2 or 3 Ra; and R3 is independently H, halogen or C1-3 alkoxy. The compound represented by formula (II) and the pharmaceutically acceptable salt thereof can better inhibit the activity of LSD1, further shows significant inhibitory activity against NCI-H1417 cell proliferation, and has good pharmacokinetic properties (including good oral bioavailability, oral exposure, half-life, and clearance rate, etc.).

Abstract: Provided is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Substituted pyridazine phenol derivatives and a preparation method therefor, specifically relating to a compound as shown in formula (VI) and a pharmaceutically acceptable salt thereof, which can be used as an NLRP3 inhibitor.

Abstract: The present invention relates to a series of fused ring derivatives containing 1,4-oxazepane and a preparation method therefor, and in particular relates to a compound as shown in formula (II) and a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure provides a system for SMS MRI. During each of a plurality of frames, the system may cause an MRI scanner to apply a plurality of PE steps to each of a plurality of slice locations of a subject to acquire echo signals. A phase modulation magnetic field gradient may be applied during each of at least some of the PE steps in the frame. For each frame, the system may reconstruct an aliasing image representative of the slice locations in the frame based on the corresponding echo signals. The system may also generate a plurality of reference slice images based on the aliasing images. The system may further reconstruct at least one slice image based on the aliasing images and the reference slice images. Each of the slice image may be representative of one of the slice locations in one of the frames.

Abstract: Disclosed are an acetophenone oxime compound and a preparation method therefor, and specifically disclosed are a compound as shown in formula (II) and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a series of benzo 2-azaspiro[4.4]nonane compounds, and specifically disclosed are a compound as represented by formula (P) or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a series of benzo 2-azaspiro[4.4]nonane compounds, and specifically disclosed are a compound as represented by formula (P) or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed in the present invention are a series of tricyclic compounds, and particularly disclosed are a compound shown in formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a class of pyrazole compounds and applications thereof in the preparation of a medicament for treating related diseases. Specifically, related are a compound represented by formula (II) and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are pyrrolotriazine compounds which act as a mitogen-activated protein kinase interacting kinase (MNK) inhibitor, and the use thereof in the preparation of a mitogen-activated protein kinase interacting kinase inhibitor drug. Specifically disclosed are compounds represented by formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: A cyclopropylamine compound as a lysine-specific demethylase 1 (LSD1) inhibitor. Particularly, the present invention relates to a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. The present invention also provides an application of the same in preparing a drug for treating an LSD1-related disease.

Abstract: Disclosed is a class of new aryl-phosphorus-oxygen compounds as shown in formula (I) as EGFR kinase inhibitors, and pharmaceutically acceptable salts thereof.

Abstract: Provided are a salt of an EGFR inhibitor, a crystal form thereof and a preparation method therefor, and an application of the salt and the crystal form in the preparation of a treatment for non-small cell lung cancer. The salt has a structure as shown in formula (II).

Abstract: Disclosed are a class of pyrazole compounds and applications thereof in the preparation of a medicament for treating related diseases. Specifically, related are a compound represented by formula (II) and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a class of isoquinoline compounds acting as RHO protein kinase inhibitors, and the use thereof in the preparation of a drug for treating diseases associated with RHO protein kinase. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof.

Abstract: Provided are a compound III serving as an LSD1 inhibitor and a crystal form thereof, as well as use of the compound and the crystal form thereof in preparation of a medicament for treating an LSD1 related disease.

Abstract: Disclosed is an application of a series of dimethylphosphine oxide compounds in the preparation of an LRRK2 kinase activity inhibitor-related drug, specifically an application of the compound shown in formula (I) or a pharmaceutically acceptable salt thereof in the preparation of an LRRK2 kinase activity inhibitor-related drug.